Home > Cardiology > ESC 2020 > Late-Breaking Science > Antisense APOC3 oligonucleotide lowers triglyceride and atherogenic lipoproteins

Antisense APOC3 oligonucleotide lowers triglyceride and atherogenic lipoproteins

Presented By
Prof. Jean-Claude Tardif, University of Montréal, Canada

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ESC 2020
Trial
Phase 2, AKCEA-APOCIII-LRx study
Targeting apolipoprotein C-III (apoC-III) mRNA may reduce the residual cardiovascular (CV) risk in patients with hypertriglyceridaemia and either established cardiovascular disease (CVD) or high CV risk. This was suggested by the findings of the phase 2 AKCEA-APOCIII-LRx study, which showed that treatment with this compound resulted in dose-dependent reductions of apoC-III, triglyceride levels, and other atherogenic lipoproteins compared with placebo [1]. Hypertriglyceridaemia is associated with severely increased CV risk in patients who, despite maximal treatment with lipid-lowering therapies, retain elevated lipid profiles. ApoC-III is a crucial regulator of the hepatic uptake of triglyceride-rich lipoproteins and plasma triglyceride levels. In addition, apoC-III may exert pro-atherogenic effects by enhancing vessel wall inflammation. As such, targeting apoC-III is an attractive approach to ameliorate excess triglyceride-rich lipoproteins, su...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on